Person: KARLI, HAMDİ NECDET
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARLI
First Name
HAMDİ NECDET
Name
19 results
Search Results
Now showing 1 - 10 of 19
Publication Can ID MigraineTM be used as a screening test for adolescent migraine?(Blackwell Publishing, 2008-04-01) Zarifoğlu, Mehmet; Karlı, Necdet; Taşkapılıoğlu, Özlem; ZARİFOĞLU, MEHMET; KARLI, HAMDİ NECDET; Taşkapılıoğlu, Özlem; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0003-4436-3797; AAK-6623-2020; EHN-5825-2022; JDE-9380-2023Publication Cgrp: New focus in migraine(Galenos Publ House, 2022-03-01) Bıçakçı, Şebnem; Bozkurt, Manal Mehtar; Karlı, Necdet; KARLI, HAMDİ NECDET; Tıp Fakültesi; Nöroloji Ana Bilim DalıMigraine is a neurological disorder characterized by recurrent attacks of headache usually accompanied by symptoms such as nausea, vomiting, photophobia and phonophobia. According to the Global Burden of Disease Study 2019 estimates, it affects more than 1.12 billion people worldwide and is a major cause of disability worldwide. Although migraine has been recognized for centuries, its pathophysiology has not been fully understood yet. Several theories have been proposed so far, the most recent being the neurovascular theory. Supported by the developments in neuroradiology and immunohistochemistry, the theory emphasizes the essential role of the trigeminovascular (TGV) system in migraine pathophysiology. It is obvious that the TGV system, regulating the cranial blood flow and nociceptive transmission, contributes to initiation and progression of serial complex events associated with migraine. The identification of vasoactive neuropeptides which had a role in migraine pathophysiology also created an opportunity for development of new treatment strategies in migraine. Calcitonin gene related peptide (CGRP) is one of the neurotransmitters that has attracted most attention since it is abundantly found in the TGV system and plays a significant role in different processes of migraine including vasodilation, neurogenic inflammation, peripheral and central sensitization. It became the focus of research in the last few decades and extensively investigated. Both small molecules antagonizing CGRP receptor and monoclonal antibodies targeting either CGRP or its receptor have been developed and used in migraine treatment. This article overviews the role of the TGV system in migraine pathophysiology and treatment with a specific focus on CGRP.Publication Real-life experiences with galcanezumab disclosed new predictors for response(Sage Publications, 2023-09-01) Dikmen, Pınar Yalınay; Baykan, Betuül; Uludüz, Derya; Özge, Aynur; Aydınlar, Elif Ilgaz; Polat, Burcu; Karlı, Necdet; Tepe, Nermin; Çelebisoy, Neşe; Toktaş, Hayal Ergin; Niflioğlu, Buket; Karacı, Rahşan; Domaç, Fusun Mayda; Uluduz, Ezgi; Soyukibar, Tuba Erdoğan; Öksüz, Nevra; Ertaş, Mustafa; KARLI, HAMDİ NECDET; Tıp Fakültesi; JDE-9380-2023Publication Association of brain volume and cognition in the chronic and episodic migraine patients(Sage Publications, 2013-06-01) Zarifoğlu, Mehmet; Şener, D. K.; Karlı, Nejdet; Hakyemez, Bahattin; Taşkapılıoğlu, Özlem; Özbek, Sevda Erer; Bakar, Mustafa; ZARİFOĞLU, MEHMET; Şener, D. K.; KARLI, HAMDİ NECDET; HAKYEMEZ, BAHATTİN; Taşkapılıoğlu, Özlem; ERER ÖZBEK, ÇİĞDEM SEVDA; BAKAR, HACI MUSTAFA; Tıp Fakültesi; Nöroloji Bölümü; 0000-0003-4436-3797; AAI-2318-2021; AAK-6623-2020; EHN-5825-2022; IOZ-7564-2023; CXD-7623-2022; DLN-1836-2022; EKN-8251-2022Publication Insight into pain syndromes in acute phase of mild-to-moderate covid-19: Frequency, clinical characteristics, and associated factors(Wiley, 2021-10-26) Karli, Necdet; KARLI, HAMDİ NECDET; Gullu, Gizem; GÜLLÜ, GİZEM; Kilic, Erhan; KILIÇ, ERHAN; Dinc, Yasemin; DİNÇ, YASEMİN; Ursavas, Ahmet; URSAVAŞ, AHMET; Yilmaz, Emel; YILMAZ, EMEL; Zarifoglu, Mehmet; ZARİFOĞLU, MEHMET; Tıp Fakültesi; 0000-0002-3894-1231; IUQ-6999-2023; AAI-3169-2021; IZQ-0662-2023; AAD-1271-2019Background Pain has been frequently described as a clinical feature of COVID-19, and the main pain syndromes that have been associated with the acute phase of this disease so far are headache, myalgia, arthralgia, and neuropathic pain. Understanding the characteristics of pain symptoms is crucial for a better clinical approach. Methods Patients who were diagnosed as having COVID-19 using reverse transcription-polymerase chain reaction were included in the study. Patients were asked to complete a 51-item questionnaire via a phone interview, which included questions on demographics, acute COVID-19 symptoms, the presence of pain symptoms, and their characteristics in the acute phase of COVID-19. Results A total of 222 out of 266 patients with COVID-19 participated in the study, yielding a response rate of 83.5%. A total of 159 patients reported at least one kind of pain syndrome with a prevalence of 71.6%. Myalgia was reported in 110 (49.6%) patients, headache in 109 (49.1%), neuropathic pain symptoms in 55 (24.8%), and polyarthralgia in 30 (13.5%) patients. A total of 66 patients reported only one type of pain, 46 reported two types, 42 reported three types, and five patients reported all four types of pain. Logistic regression analysis showed that there were significant associations between these pain syndromes and a strong association was found between neuropathic pain and headache. Conclusion Pain is a frequently observed symptom of mild-to-moderate COVID-19. There are significant relationships between pain syndromes in COVID-19, which may be due to a sequence of common etiologic factors. Significance This study described the main pain syndromes associated acute phase of mild-to-moderate COVID-19 and its associated features. Headaches and pain of neuropathic characteristics were prevalent in this sample.Publication Evaluation of the effects of botulinum toxin therapy on the clinical characteristics of pain and pain threshold value in patients with primary cervical dystonia(Journal Neurological Sciences, 2015-01-01) Özbek, Sevda Erer; Karlı Necdet; Yurtoğulları, Şükran; Zarifoğlu, Mehmet; Ocakoğlu, Gökhan; ERER ÖZBEK, ÇİĞDEM SEVDA; KARLI, HAMDİ NECDET; YURTOĞULLARI, ŞÜKRAN; ZARİFOĞLU, MEHMET; OCAKOĞLU, GÖKHANObjective: In 70% of patients with cervical dystonia (CD), the clinical presentation includes the symptom of pain. In this study, we aimed to define the types and clinical characteristics of the pain and to investigate whether this pain is a result of central sensitization by evaluating pre- and post-botulinum toxin (BoNT) treatment pain threshold values using electrical stimulation.Methods: The study enrolled a total of 35 patients with CD who received BoNT therapy. The patients were evaluated using the pain evaluation scale and Unified Dystonia Rating scale (UDRS) before and after BoNT therapy. The pain threshold values obtained from dystonic muscles, the contiguous or contralateral muscle without dystonic activity and a normal reference muscle with distant localization were recorded through electrical stimulation with EMG guidance, and all values obtained before and after BoNT therapy were compared.Results: No difference was found between the pain threshold values obtained from dystonic muscles before and after treatment. While no difference was observed across genders or VAS groups in terms of pain threshold values, the UDRS (duration and motor severity factor) scores showed significant decreases after treatment with BoNT in patients with painful dystonia and in patients with painless dystonia.Conclusions: The absence of a difference in pre- and post-BoNT treatment pain threshold values in dystonic muscles might be explained by the absence of central sensitization. Pain relief in dystonic patients might occur secondary to decreases in dystonic muscle contractions.Publication Migraine and E-TTH: Do they have similar clinical features and pathophysiologic mechanisms?(Blackwell Publishing Ltd, 2003-09-01) Karlı, Necdet; Zarifoğlu, Mehmet; Çalışkan, Nalan; KARLI, HAMDİ NECDET; ZARİFOĞLU, MEHMET; Çalışkan, Nalan; Tıp Fakültesi; Nöroloji Bölümü; JDE-9380-2023; EHN-5825-2022; EOX-5138-2022Publication Real-life experiences with galcanezumab and predictors for treatment response in Turkey(BMC, 2023-11-23) Yalınay Dikmen, Pınar; Baykan, Betuel; Uludüz, Derya; Özge, Aynur; Ilgaz Aydınlar, Elif; Polat, Burcu; Karlı, Necdet; Tepe, Nermin; Çelebisoy, Neşe; Ergin Toktaş, Hayal; Niflioğlu, Buket; Karaci, Rahşan; Mayda Domaç, Füsün; Uludüz, Ezgi; Erdoğan Soyukibar, Tuba; Öksuez, Nevra; Ertaş, Mustafa; KARLI, HAMDİ NECDET; Tıp Fakültesi; D-2590-2015BackgroundThe complexity of clinical practice extends far beyond the controlled settings of trials, and there is a need for real-world studies aimed at identifying which patients will respond to anti-CGRP monoclonal antibodies in different countries. This study aimed to investigate the efficacy and safety of galcanezumab in treating migraine in a real-life setting in Turkey, as well as identify predictors of treatment response.MethodsA total of 476 patients who diagnosed with migraine according to ICHD-3 criteria and treated with galcanezumab by headache specialists were voluntarily participated in this cross-sectional study. Galcanezumab is indicated for the prevention of migraine in adults who have at least 4 monthly migraine days in Turkey. All patients filled out a survey on Google Form that comprised 54 questions, addressing various aspects such as demographics, migraine characteristics, previous use of acute symptomatic medication, failures with preventive drug classes, comorbidities, most bothersome symptoms, as well as the interictal burden of migraine.ResultsAmong the participants, 89.3% reported that galcanezumab treatment was beneficial for them. A decrease in the frequency (80.0%), severity (85.7%), and acute medication usage for migraine attacks (71.4%) was reported with galcanezumab treatment. An adverse effect related to galcanezumab was reported in 16.3% of cases, but no serious adverse reactions were observed. Remarkably, 14.3% of participants reported no longer experiencing any headaches, and 18.9% did not require any acute treatment while receiving galcanezumab treatment. A logistic regression model showed that male gender, lack of ictal nausea, and previous failure of more than 2 prophylactic agents may predict the non-responders.ConclusionsThe first large series from Turkey showed that galcanezumab treatment is safe and effective in most of the patients diagnosed with migraine by headache experts in the real-life setting. Patients reported a significant decrease in both ictal and interictal burden of migraine and expressed satisfaction with this treatment.Publication IVIg-induced headache: prospective study of a large cohort with neurological disorders(Springer-Verlag Italia Srl, 2023-03-11) Bayir, Buse Rahime Hasirci; Ünsal, Mirac Aysen; Agircan, Cansu; Sirin, Tuba Cerrahoglu; Akan, Onur; Gursoy, Gizem; Eyigurbuz, Tugba; Dibek, Dilara Mermi; Akdag, Gonul; Elmali, Ayse Deniz; Nazli, Ezgi; Arikan, Fatma Akkoyun; Baslo, Sezin Alpaydin; Agircan, Dilek; Oğuz-Akarsu, Emel; Cetin, Özdem Ertürk; Demir, Tulin Gesoglu; Demirel, Esra Aciman; Vuralli, Doğa; Deveci, Şule; Tanyel, Tuba; Domac, Fusun Mayda; Karlı, Necdet; Velioglu, Sibel; Baykan, Betul; OĞUZ AKARSU, EMEL; KARLI, HAMDİ NECDET; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; IZQ-0662-2023; JDE-9380-2023BackgroundIntravenous immune globulin (IVIg) is frequently used in some neurological diseases and is also the first-line therapy in Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. We aimed to evaluate the frequency and characteristics of headaches, which is one of the most common side effects of IVIg treatment.MethodsPatients who received IVIg treatment for neurological diseases were prospectively enrolled in 23 centers. Firstly, the characteristics of patients with and without IVIg-induced headaches were analyzed statistically. Then, patients with IVIg-induced headaches were classified into three subgroups determined by their history: no primary headache, tension-type headache (TTH), and migraine.ResultsA total of 464 patients (214 women) and 1548 IVIg infusions were enrolled between January and August 2022. The frequency of IVIg-related headaches was 27.37% (127/464). A binary logistic regression analysis performed with significant clinical features disclosed that female sex and fatigue as a side effect were statistically more common in the IVIg-induced headache group. IVIg-related headache duration was long and affected daily living activities more in patients with migraine compared to no primary headache and TTH groups (p = 0.01, respectively).ConclusionHeadache is more likely to occur in female patients receiving IVIg and those who develop fatigue as a side effect during the infusion. Clinicians' awareness of IVIg-related headache characteristics, especially in patients with migraine, may increase treatment compliance.Publication Transthyretin familial amyloid polyneuropathy (TTR-FAP): A database analysis(Lippincott Williams & Wilkins, 2020-04-14) Erdoğan, Çağdaş; Bayrak, Ayşe Oytun; Uluç, Kayıhan; Karlı, Necdet; Koç, Filiz; Öztürk, Şerefnur; Şengün, İhsan Şükrü; Seçil, Yaprak; Tütüncü, Melih; Akalın, Mehmet Ali; Uysal, Hilmi; Özdamar, Sevim Erdem; Parman, Yeşim; KARLI, HAMDİ NECDET; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; JDE-9380-2023